---
title: "受美國食品藥品監督管理局優先權推動，Revolution Medicines 公司股價盤後大漲 13%。"
description: "受美國食品藥品監督管理局優先權推動，Revolution Medicines 公司股價盤後大漲 13%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261508838.md"
published_at: "2025-10-16T21:14:51.000Z"
---

# 受美國食品藥品監督管理局優先權推動，Revolution Medicines 公司股價盤後大漲 13%。

受美國食品藥品監督管理局優先權推動，Revolution Medicines 公司股價盤後大漲 13%。

### Related Stocks

- [RVMD.US - Revolution Medicines](https://longbridge.com/zh-HK/quote/RVMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Revolution Medicines COO Margaret Horn Reports Disposal of Common Shares | Margaret A. Horn, COO of Revolution Medicines Inc., has reported the disposal of common shares of the company. The detai | [Link](https://longbridge.com/zh-HK/news/270209739.md) |
| Revolution Medicines Showcases Pipeline Progress and Phase 3 Trials Targeting RAS-Driven Cancers | Revolution Medicines Inc. has updated its clinical pipeline for RAS-addicted cancers, reporting over 2,500 patients trea | [Link](https://longbridge.com/zh-HK/news/272308108.md) |
| FDA Grants Breakthrough Therapy Designation to Revolution Medicines' Zoldonrasib for KRAS G12D-Mutated NSCLC | Revolution Medicines Inc. announced that the FDA has granted Breakthrough Therapy Designation to zoldonrasib, a selectiv | [Link](https://longbridge.com/zh-HK/news/271936850.md) |
| Revolution Medicines Launches Phase 3 Trial of Daraxonrasib in Resectable Pancreatic Cancer | Revolution Medicines Inc. has initiated a Phase 3 clinical trial, RASolute 304, for daraxonrasib in patients with resect | [Link](https://longbridge.com/zh-HK/news/270162709.md) |
| Here's How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years | Revolution Medicines (NASDAQ:RVMD) has outperformed the market by 13.22% annually over the past 5 years, yielding an ave | [Link](https://longbridge.com/zh-HK/news/272138799.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。